{"title":"Primary Hyperparathyroidism with Severe Vitamin D Deficiency in Chronic Kidney Disease.","authors":"Tsuyoshi Oshiro, Hiroki Nishiwaki, Reiji Takami, Shinya Omiya, Edward Barroga, Fumihiko Koiwa","doi":"10.2169/internalmedicine.5467-25","DOIUrl":null,"url":null,"abstract":"<p><p>A 71-year-old woman with altered consciousness was diagnosed with primary hyperparathyroidism (PHPT) after presenting with severe hypercalcemia (serum Ca 15.3 mg/dL) and parathyroid adenoma. Unusually, her 1,25(OH)<sub>2</sub>D<sub>3</sub> level was undetectable, despite PHPT. Hemodialysis and evocalcet failed to control the calcium levels, but denosumab effectively reduced hypercalcemia. However, both 25(OH)D<sub>3</sub> and 1,25(OH)<sub>2</sub>D<sub>3</sub> remained low. This case highlights the importance of vitamin D assessment in PHPT, as its metabolism can vary. Denosumab may be a viable treatment option for calcimimetic hypercalcemia.</p>","PeriodicalId":520650,"journal":{"name":"Internal medicine (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal medicine (Tokyo, Japan)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2169/internalmedicine.5467-25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A 71-year-old woman with altered consciousness was diagnosed with primary hyperparathyroidism (PHPT) after presenting with severe hypercalcemia (serum Ca 15.3 mg/dL) and parathyroid adenoma. Unusually, her 1,25(OH)2D3 level was undetectable, despite PHPT. Hemodialysis and evocalcet failed to control the calcium levels, but denosumab effectively reduced hypercalcemia. However, both 25(OH)D3 and 1,25(OH)2D3 remained low. This case highlights the importance of vitamin D assessment in PHPT, as its metabolism can vary. Denosumab may be a viable treatment option for calcimimetic hypercalcemia.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
